Pfizer reaches separate settlements with U.S. DoJ and SEC to resolve charges its subsidiaries bribed Chinese, Russian and other foreign government officials; a subsidiary enters a deferred prosecution agreement with DoJ.
Pfizer Inc.’s “extraordinary cooperation” in disclosing and dealing with a subsidiary’s improper payments to foreign officials helped the company obtain a deferred prosecution agreement for violations of the U.S. Foreign Corrupt Practices Act.
On Aug. 7, Pfizer settled two parallel investigations by the U.S. Department of Justice and the Securities and Exchange Commission...
Create an account to read this article
Already a subscriber?
Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.
Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.
While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.
Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.
The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.
Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.
The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.
